Clinical trials: Advanced Cutaneous Melanoma of the Extremity
Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity
CBL0137 in Treating Patients With Advanced Extremity Melanoma or Sarcoma
This phase I trial studies best dose and side effects of CBL0137 in treating patients with extremity melanoma or sarcoma that has spread to other places in the body.
- Conditions
- Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8
- Trial name
- NCT03727789
- Testing
- FACT Complex-targeting Curaxin CBL0137
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Roswell Park Cancer Institute
Recurrent Melanoma, Stage III Melanoma
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg
Randomized phase III trial to compare the effectiveness of hyperthermic isolated limb perfusion of melphalan with or without tumor necrosis factor in treating patients who have locally advanced melanoma of the arm or leg.
- Trial name
- NCT00003789
- Testing
- isolated limb perfusion, melphalan, recombinant tumor necrosis factor family protein
- Where
- United States
- Volunteers
- 216 people
- Sponsor
- National Cancer Institute (NCI)
Melanoma and Sarcoma
TITAN (Tumoural Injection of T-VEC and Isolated Limb Perfusion)
This study will look at the safety and effects of combining a new drug called Talimogene Laherparepvec (T-VEC) with chemotherapy delivered by Isolated Limb Perfusion (ILP).
- Trial name
- TITAN (NCT03555032)
- Testing
- Talimogene laherparepvec (T-VEC)
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- Royal Marsden NHS Foundation Trust
Melanoma
A Randomized Phase III Trial of Hyperthermic Isolated Limb Perfusion With Melphalan, Tumor Necrosis Factor, and Interferon-Gamma in Patients With Locally Advanced Extremity Melanoma
Randomized study. Initially, 3 patients will be entered on Arm I as a pilot feasibility study and to standardize the technical aspects of the study. Subsequently, all patients are randomized to Arms I and II.
- Trial name
- NCT00001296
- Testing
- melphalan, tumor necrosis factor, interferon-gamma
- Where
- United States
- Volunteers
- 122 people
- Sponsor
- National Cancer Institute (NCI)
Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin
Isolated Limb Perfusion With Melphalan in Treating Patients With Stage IIIB-IV Melanoma or Sarcoma
This pilot clinical trial studies isolated limb perfusion with melphalan in treating patients with stage IIIB-IV melanoma or sarcoma.
- Conditions
- Basal Cell Carcinoma of the Skin, Eccrine Carcinoma of the Skin, Recurrent Adult Soft Tissue Sarcoma, Recurrent Melanoma
- Trial name
- NCT02507076
- Testing
- isolated limb perfusion, melphalan, quality-of-life assessment
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Melanoma
Addition of Ipilimumab (MDX-010) To Isolated Limb Infusion (ILI) With Standard Melphalan and Dactinomycin In The Treatment of Advanced Unresectable Melanoma of The Extremity
The purpose of this study is to see the effect of adding a systemic study drug, Ipilimumab, to two standard chemotherapy drugs, Melphalan and Dactinomycin.
- Trial name
- NCT01323517
- Testing
- Ipilimumab, Melphalan and Dactinomycin
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Melanoma
Evaluate Safety/Tolerability Intra-Arterial Temozolomide in Patients w/Extremity Melanoma by Isolated Limb Infusion
The purpose of this study is to determine the safety profile of intra-arterial temozolomide administration during Isolated Limb Infusion (ILI) by defining the dose limiting toxicities associated with this treatment.
- Trial name
- NCT01127594
- Testing
- Temozolomide
- Where
- 3 sites in United States
- Volunteers
- 29 people
- Sponsor
- Douglas Tyler